A5070143246- CAR-T cell therapy research
- Research on Leishmaniasis Studies
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Cancer Immunotherapy and Biomarkers
- Viral Infectious Diseases and Gene Expression in Insects
- Trypanosoma species research and implications
- Leptospirosis research and findings
- T-cell and Retrovirus Studies
- T-cell and B-cell Immunology
- Administrative Law and Governance
- Erythrocyte Function and Pathophysiology
- Cancer Research and Treatments
- Vector-borne infectious diseases
- Malaria Research and Control
- Neuroblastoma Research and Treatments
- Dermatological diseases and infestations
- Comparative constitutional jurisprudence studies
- Legal processes and jurisprudence
- Vector-Borne Animal Diseases
City of Hope
2022-2024
City Of Hope National Medical Center
2023
Yale University
2020-2021
Universidad de Extremadura
2013-2020
Institute of Parasitology
2005
Tumor-specific CD8 + T cells in stable tumor-draining lymph node reservoir are clonally and developmentally related to those tumors.
Abstract Chimeric antigen receptor (CAR) T cell therapeutic responses are hampered by limited trafficking, persistence, and durable anti-tumor activity in solid tumors. However, these challenges can be largely overcome relatively unconstrained synthetic engineering strategies. Here, we describe CAR cells targeting tumor-associated glycoprotein-72 (TAG72), utilizing the CD28 transmembrane domain upstream of 4-1BB co-stimulatory as a driver potent IFNγ secretion. cell-mediated production...
ABSTRACT In a previous work, we demonstrated that the induction of arginase I favored replication Leishmania inside macrophages. Now have analyzed differential expression this enzyme in mouse model L. major infection. Ours results show is induced both susceptible and resistant mice during development disease. However, BALB/c-infected tissues, protein parallels time infection, while C57BL/6 mice, upregulated only footpad swelling. The host strains mediated by balance between interleukin-4...
Canine leishmaniosis is a zoonotic disease caused by Leishmania infantum. Extensive research currently ongoing to develop safe and effective vaccines protect from development. The European Commission has granted marketing authorization for LetiFend®, new vaccine containing recombinant Protein Q. efficacy of LetiFend® vaccination in large-scale dog population both sexes, different breeds ages endemic areas reported this multicenter, randomized, double-blind, placebo-controlled field trial....
El acceso a internet ha evolucionado de ser una herramienta opcional un recurso esencial para el ejercicio derechos fundamentales como la educación, trabajo y participación democrática. Este artículo analiza protección del derecho al en Colombia desde enfoque jurídico, considerando su reconocimiento progresivo servicio público rol reducción brecha digital. A través revisión normatividad jurisprudencia, se identifican los desafíos avances implementación, con énfasis impacto comunidades...
Abstract “Stem-like” TCF1 + CD8 T cells (T SL ) are necessary for long-term maintenance of cell responses and the efficacy immunotherapy but, as tumors contain signals that should drive T-cell terminal-differentiation, how these maintained in remains unclear. We found a small number tumor-specific were present throughout development. Yet, most intratumoral differentiated progressed, corresponding with an immunologic shift tumor microenvironment (TME) from “hot” to “cold”. By contrast,...
Malaria has been for millennia one of the best known and most destructive diseases affecting humans. Its high impact aroused great interest development new effective reliable diagnostic techniques. Recently it recently published that hairs from mammal hosts are able to capture, hold finally remove foreign DNA sequences Leishmania parasites. The aim this study was check if Plasmodium falciparum (P. falciparum) remains stable in blood samples deposited Whatman paper after suffering different...
Intratumoral stem-like CD8+ T cells (TSL) are necessary for immunotherapeutic efficacy. Yet, tumors rich in signals driving terminal differentiation of TSL into exhausted cells. Using the “KP-NINJA” lung tumor model, we determined that tumor-specific terminally differentiate tumors, but they maintained by a reservoir from tumor-draining lymph node (dLN). By tracing clones using single-cell RNA/TCRseq, found dLN were developmental precursors more differentiated intratumoral cell populations....
<h3>Background</h3> Autologous chimeric antigen receptor (CAR) T cell therapy has shown impressive clinical responses against CD19+ B-cell hematological malignancies and is being actively explored in the treatment of solid tumors. However, several barriers have precluded therapeutic tumors, including limited tumor-restricted CAR targets immunosuppressive tumor microenvironment. We recently reported successful combination immunotherapy using a novel vaccinia-based oncolytic virus (OV), called...
Abstract While chimeric antigen receptor (CAR) T cells have received FDA approvals in treating hematological malignancies, clinical responses of CAR for solid tumors been underwhelming. Intense investigation is underway to improve trafficking, persistence and efficacy. Interleukin-12 (IL-12) a potent inflammatory cytokine that recruits activates various endogenous adoptively transferred immune cells, but development its applications hindered by toxicity systemic IL-12 signaling. In this...
Abstract Mouse models with inducible neoantigens have been historically difficult to generate because of leaky expression antigens in the thymus, which causes central tolerance developing CD8 and CD4 T cells. Attempts resolve this problem using existing genetic tools unsuccessful. We developed iNversion INducible Joined neoAntigen (NINJA) mouse model that uses RNA splicing, DNA recombination, three levels regulation prevent neoantigen leakiness allow tight control over induction expression....
<h3>Background</h3> Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths in world with a 5-year survival rate at less than 12%. Currently, curative treatments include ablation, surgical resection, and liver transplantation. For majority patients advanced-stage disease, treatment agents such as sorafenib, lenvatinib, atezolizumab/bevacizumab other investigational yield modest success rates justify need for further development new therapies. T cell therapy...
<h3>Background</h3> Bispecific T cell engager (BiTE) monoclonal antibodies have emerged as a promising immunotherapy strategy for the treatment of hematological malignancies. Blinatumomab, an FDA approved BiTE carrying CD19 and CD3 epitopes has shown durable clinical responses B-cell acute lymphoblastic leukemia (B-ALL) non-Hodgkins lymphomas. Despite wide array research in malignancies, therapies solid tumors remained significant challenge demonstrating comparable efficacy. Solid often lack...